Clinical Trial Update: Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants [Phase 2]

View source ↗

Summary

This update reports that the Phase 2 extension study of LTP001 in pulmonary arterial hypertension has been terminated. Results from the terminated study have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• LTP001

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: TERMINATED | Results posted: 2025-12-26